MedTrace Logo

Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae

NCT04790565 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-10-26

No results posted yet for this study

Summary

Open-label, single center, prospective interventional non-comparative study for CRE carriers.

Conditions

  • Carbapenem-Resistant Enterobacteriaceae Infection

Interventions

BIOLOGICAL

FMT

Fecal microbiota in frozen capsules

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Michal Paul, MD · Rambam Health Care Campus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-06-30
Completion
2022-10-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04790565 on ClinicalTrials.gov